Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication
AstraZeneca’s flagship cancer drug is adding a new indication to its fleet.
Friday afternoon, the FDA granted Tagrisso the thumbs-up in non-small cell lung cancer for patients with EGFR mutations who had undergone tumor resection and optional, standard postoperative adjuvant chemotherapy. It’s another win for the drug as a prominent rival from J&J continues to play catch-up.
The drug, which is on pace to eclipse $4 billion in sales for 2020, had previously been approved in first line metastatic EGFR-mutated NSCLC and second-line metastatic NSCLC patients with EGFR T790M mutations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.